A detailed history of Raymond James Financial Services Advisors, Inc. transactions in Infla Rx N.V. stock. As of the latest transaction made, Raymond James Financial Services Advisors, Inc. holds 381,113 shares of IFRX stock, worth $987,082. This represents 0.0% of its overall portfolio holdings.

Number of Shares
381,113
Previous 376,914 1.11%
Holding current value
$987,082
Previous $655,000 10.99%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$1.34 - $1.73 $5,626 - $7,264
4,199 Added 1.11%
381,113 $583,000
Q2 2024

Jul 19, 2024

SELL
$1.18 - $1.74 $9,508 - $14,020
-8,058 Reduced 2.09%
376,914 $655,000
Q1 2024

Apr 22, 2024

BUY
$1.47 - $2.03 $98,656 - $136,239
67,113 Added 21.11%
384,972 $592,000
Q4 2023

Jan 16, 2024

BUY
$1.25 - $2.75 $61,180 - $134,596
48,944 Added 18.2%
317,859 $518,000
Q3 2023

Oct 24, 2023

BUY
$2.66 - $4.33 $223,913 - $364,490
84,178 Added 45.57%
268,915 $801,000
Q2 2023

Jul 25, 2023

BUY
$2.05 - $6.1 $62,180 - $185,025
30,332 Added 19.64%
184,737 $823,000
Q1 2023

Apr 14, 2023

BUY
$1.66 - $3.1 $36,403 - $67,983
21,930 Added 16.55%
154,405 $299,000
Q4 2022

Feb 08, 2023

BUY
$2.11 - $3.25 $44,706 - $68,861
21,188 Added 19.04%
132,475 $410,000
Q3 2022

Oct 25, 2022

SELL
$1.32 - $3.14 $41,950 - $99,792
-31,781 Reduced 22.21%
111,287 $294,000
Q2 2022

Aug 12, 2022

SELL
$0.78 - $1.9 $4,302 - $10,480
-5,516 Reduced 3.71%
143,068 $207,000
Q1 2022

May 11, 2022

BUY
$1.83 - $4.48 $96,825 - $237,036
52,910 Added 55.3%
148,584 $272,000
Q4 2021

Feb 08, 2022

BUY
$2.35 - $5.58 $192,197 - $456,365
81,786 Added 588.9%
95,674 $455,000
Q3 2021

Nov 02, 2021

SELL
$2.25 - $3.03 $21,280 - $28,657
-9,458 Reduced 40.51%
13,888 $36,000
Q2 2021

Aug 11, 2021

SELL
$2.72 - $4.04 $10,058 - $14,939
-3,698 Reduced 13.67%
23,346 $69,000
Q1 2021

May 14, 2021

SELL
$3.62 - $6.34 $22,082 - $38,674
-6,100 Reduced 18.4%
27,044 $105,000
Q4 2020

Feb 12, 2021

SELL
$3.82 - $5.32 $56,600 - $78,826
-14,817 Reduced 30.89%
33,144 $167,000
Q3 2020

Nov 04, 2020

SELL
$3.7 - $5.47 $34,373 - $50,816
-9,290 Reduced 16.23%
47,961 $204,000
Q2 2020

Jul 17, 2020

BUY
$4.59 - $8.96 $262,782 - $512,968
57,251 New
57,251 $263,000

Others Institutions Holding IFRX

About InflaRx N.V.


  • Ticker IFRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 44,203,800
  • Market Cap $114M
  • Description
  • InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...
More about IFRX
Track This Portfolio

Track Raymond James Financial Services Advisors, Inc. Portfolio

Follow Raymond James Financial Services Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.